Publications

Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hoffman WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood. 2013 Jan 14. View in: PubMed PDF
Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR. Both CpG Methylation and Activation-Induced Deaminase Are Required for the Fragility of the Human bcl-2 Major Breakpoint Region: Implications for the Timing of the Breaks in the t(14;18) Translocation. Mol Cell Biol. 2013 Mar;33(5):947-57. View in: PubMed PDF
Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2013 Jan 3;121(1):148-55. View in: PubMed PDF
Bicocca VT, Chang BH, Masouleh BK, Müschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012 Nov 13;22(5):656-67. View in: PubMed PDF
Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012 Nov;2(11):1004-23. View in: PubMed PDF
Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, Soverini S, Pane F, Foà R, Baccarani M, Müschen M, Perini G, Martinelli G. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 2012;7(7):e40934 View in: PubMed PDF
Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, Choudhry P, Manos EJ, Sofla H, Sanati A, Welborn S, Agarwal A, Spangrude GJ, Miles RR, Cox JE, Frazer JK, Deininger M, Balan K, Sigman M, Müschen M, Perova T, Johnson R, Montpellier B, Guidos CJ, Jones DA, Trede NS. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 2012 Jun 14;119(24):5621-31. View in: PubMed PDF
Jiang XX, Nguyen Q, Chou Y, Wang T, Nandakumar V, Yates P, Jones L, Wang L, Won H, Lee HR, Jung JU, Müschen M, Huang XF, Chen SY. Control of B Cell Development by the Histone H2A Deubiquitinase MYSM1. Immunity 2011 Dec 23; 35(6):883-96. View in: PubMed PDF
Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011 Oct 24; 208(11):2163-74 View in: PubMed PDF
Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood 2011 Oct 13; 118(15):4174-8 View in: PubMed PDF Supplemental
Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011 Aug 25; 118(8):2191-9 View in: PubMed PDF
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M. BCL6 enables Ph(+) acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011 May 19; 473(7347):384-8 View in: PubMed PDF Supplemental
Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Müschen M, Grant S. HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo. Clin Cancer Res 2011 May 15; 17(10):3219-32 View in: PubMed PDF
Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between bcr-abl and negative feedback mechanisms controlling SRC signaling. Sci Signal 2011; 4(166):ra18 View in: PubMed PDF
Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia 2011 Feb; 25(2):290-300 View in: PubMed PDF
Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Res 2010 Oct 1; 70(19):7411-20 View in: PubMed PDF
Fang C, Wang Y, Vu NT, Lin WY, Hsieh YT, Rubbi L, Phelps ME, Müschen M, Kim YM, Chatziioannou AF, Tseng HR, Graeber TG. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res 2010 Nov 1; 70(21):8299-308 View in: PubMed PDF
Yun JP, Behan JW, Heisterkamp N, Butturini A, Klemm L, Ji L, Groffen J, Müschen M, Mittelman SD. Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila) 2010 Oct; 3(10):1259-64 View in: PubMed PDF
Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, Jumaa H, Koeffler HP, de Alborän IM, Melnick AM, Ye BH, Müschen M. BCL6 is critical for the development of a diverse primary B cell repertoire. J Exp Med 2010 Jun 7; 207(6):1209-21 View in: PubMed PDF
Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 2010 Jun 1; 70(11):4346-56 View in: PubMed PDF
Müschen M. Genetic relicts from the origin of ALL. Blood 2010 Apr 29; 115(17):3424-5 View in: PubMed PDF
Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. J Cell Biochem 2010 Mar 1; 109(4):818-27 View in: PubMed PDF
Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010 Apr; 24(4):813-20 View in: PubMed PDF
Nahar R, Müschen M. Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle 2009 Dec; 8(23):3874-7 View in: PubMed PDF
Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Thoenissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2010 Feb 4; 115(5):1049-53 View in: PubMed PDF
Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009 Sep 8; 16(3):232-45 View in: PubMed PDF Supplemental
Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Müschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 2009 Aug 3; 206(8):1739-53 View in: PubMed PDF
Tsai AG, Lu H, Raghavan SC, Müschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 2008 Dec 12; 135(6):1130-42 View in: PubMed PDF
Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Müschen M, Foä R, Baccarani M, Martinelli G. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica 2008 Dec; 93(12):1814-21 View in: PubMed PDF
Müschen M. Highlight: self-renewal signaling in stem cells. Biol Chem 2008 Jul; 389(7):787 View in: PubMed PDF
Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biol Chem 2008 Jul; 389(7):897-903 View in: PubMed PDF
Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007; 6:67 View in: PubMed PDF
Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med 2007 May 14; 204(5):1157-66 View in: PubMed PDF
Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007 Mar; 26(3):323-33 View in: PubMed PDF
Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen NS, Greeve J, Parwaresch R. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. J Pathol 2006 Jun; 209(2):250-7 View in: PubMed PDF
Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells. Oncogene 2006 Aug 24; 25(37):5180-6 View in: PubMed PDF
Sprangers M, Feldhahn N, Herzog S, Hansmann ML, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene 2006 Aug 17; 25(36):5056-62 View in: PubMed PDF
Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006 Feb 16; 25(7):1118-24 View in: PubMed PDF
Feldhahn N, RÍo P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci U S A 2005 Sep 13; 102(37):13266-71 View in: PubMed PDF
Soh BN, Klein F, Feldhahn N, Müschen M. B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet 2005 Sep; 161(2):187-8 View in: PubMed PDF
Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 2005 Jun 6; 201(11):1837-52 View in: PubMed PDF
Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol 2005 Jan 1; 174(1):367-75 View in: PubMed PDF
Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. Eur J Immunol 2004 Dec; 34(12):3614-22 View in: PubMed PDF
Klein F, Feldhahn N, Müschen M. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. Cell Cycle 2004 Jul; 3(7):858-60 View in: PubMed PDF
Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, Caplan AI, Colletti EJ, Almeida-Porada G, Müller HW, Zanjani E, Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004 Jul 19; 200(2):123-35 View in: PubMed PDF
Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med 2004 Mar 1; 199(5):673-85 View in: PubMed PDF
Schuster VH, Müschen M. Epstein-Barr virus and the B cell: a secret romance. Trends Microbiol 2003 Jun; 11(6):243-5 View in: PubMed PDF
Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M. T lymphoid differentiation in human bone marrow. Proc Natl Acad Sci U S A 2003 May 27; 100(11):6747-52 View in: PubMed PDF
Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003 Mar; 17(3):503-5 View in: PubMed PDF
Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM. Molecular portraits of B cell lineage commitment. Proc Natl Acad Sci U S A 2002 Jul 23; 99(15):10014-9 View in: PubMed PDF
Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol 2002 Feb; 23(2):75-80 View in: PubMed PDF
Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. Int J Cancer 2001 Apr 15; 92(2):309-10 View in: PubMed PDF
Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML. Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. Lab Invest 2001 Mar; 81(3):289-95 View in: PubMed
Re D, Müschen M, Ahmadi T, Wickenhauser C, Staratschek-Jox A, Holtick U, Diehl V, Wolf J. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001 Mar 1; 61(5):2080-4 View in: PubMed PDF
Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood 2001 Feb 1; 97(3):818-21 View in: PubMed PDF
Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med 2000 Dec 18; 192(12):1833-40 View in: PubMed PDF
Müschen M, Re D, Bräuninger A, Wolf J, Hansmann ML, Diehl V, Küppers R, Rajewsky K. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 2000 Oct 15; 60(20):5640-3 View in: PubMed PDF
Müschen M, Beckmann MW. CD95 ligand expression as a criterion of malignant transformation in breast cancer. J Pathol 2000 Aug; 191(4):468-70 View in: PubMed PDF
Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000 Jan 17; 191(2):387-94 View in: PubMed PDF
Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 2000 Jan; 99(1):69-77 View in: PubMed PDF
Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000; 78(6):312-25 View in: PubMed PDF
Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. J Pathol 1999 Nov; 189(3):378-86 View in: PubMed PDF
Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of soluble CD95 in Churg-Strauss syndrome. Am J Pathol 1999 Sep; 155(3):915-25 View in: PubMed PDF
Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology 1999 Mar; 116(3):666-77 View in: PubMed PDF
Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin. Int J Cancer 1999 Feb 9; 80(4):564-72 View in: PubMed PDF
Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest 1998 Dec 1; 102(11):1920-6 View in: PubMed PDF
Josien R, Müschen M, Gilbert E, Douillard P, Heslan JM, Soulillou JP, Cuturi MC. Fas ligand, tumor necrosis factor-alpha expression, and apoptosis during allograft rejection and tolerance. Transplantation 1998 Oct 15; 66(7):887-93 View in: PubMed PDF
Müschen M, Warskulat U, Schmidt B, Schulz WA, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid. Biol Chem 1998 Aug-Sep; 379(8-9):1083-91 View in: PubMed
Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. Deranged CD95 system in a case of Churg-Strauss vasculitis. Gastroenterology 1998 Jun; 114(6):1351-2 View in: PubMed
Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology 1998 Jan; 27(1):200-8 View in: PubMed PDF
Müschen M, Sies H, Schulz WA. Induction of mouse embryonal carcinoma cell differentiation and activation of the retinoic acid receptor beta 2 promoter by 1,25-dihydroxyvitamin D3. Biol Chem 1996 Nov; 377(11):703-10 View in: PubMed